Jonathan Schwartz MD

Jonathan Schwartz is Chief Science and Gene Therapy Officer for Rocket Pharma, responsible for advancing Rocket’s gene therapies through critical stages in development and enhancing the Company’s dedicated focus on strategic application of gene therapy technologies to current and future therapeutic areas. Jonathan joined Rocket as the founding Chief Medical Officer in 2016 and has been instrumental in crafting and advancing an industry-leading pipeline of gene therapy programs across AAV cardiology and LV hematology portfolios.

Before Rocket, Jonathan was Vice President for Clinical Development at Stemline Therapeutics, where he oversaw early development efforts for anticancer immunoconjugate, vaccine, and small-molecule platforms. Before his role at Stemline, Jonathan had a seven-year tenure at ImClone/Eli Lilly, where he oversaw the development of the antiangiogenic monoclonal antibody Ramucirumab (CYRAMZA®) from end-of-Phase-1 through a Phase 3 program resulting in stomach, liver, lung, and colorectal cancer approvals by the FDA and international health authorities. Jonathan has also participated in the multistage development of several additional monoclonal antibodies.

Before joining the industry, Jonathan was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies; he was also Director of the Hematology-Oncology Fellowship training program. Jonathan received a Bachelor of Arts in American Civilization from Brown University and an MD from Washington University in St. Louis. He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.